BCL2L1 and Thrombocytopenia: Direct targeting of MCL-1 or BCL-XL is feasible but limited by toxicities: early MCL-1 inhibitors showed cardiac safety signals, and BCL-XL blockade causes dose-limiting thrombocytopenia (Roberts et al., 2021).